OSE — Ose Immunotherapeutics SA Balance Sheet
0.000.00%
Last trade - 00:00- €86.67m
- €45.07m
- €2.70m
Annual balance sheet for Ose Immunotherapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 33.6 | 25.6 | 18.7 | 59.1 | — |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 7.66 | 8.13 | 9.06 | 8.53 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 44.2 | 37.2 | 30.5 | 69.9 | — |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.44 | 4.98 | 4.07 | 3.42 | — |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 102 | 91.8 | 82.1 | 124 | — |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 16.8 | 16.3 | 18.8 | 20.2 | — |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 54 | 59.1 | 59.1 | 60.1 | — |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 47.9 | 32.7 | 23 | 63.8 | — |
| Total Liabilities & Shareholders' Equity | 102 | 91.8 | 82.1 | 124 | — |
| Total Common Shares Outstanding |